CD8A and neoplasm: In the EMPD cases, none of the clinical-pathologic parameters assessed (including overall survival, disease-specific survival, and time to metastasis) or the relative density of CD3+, CD8+, or PD-1+ cells in tumor-associated lymphocytes quantified by automated image analysis (positive cells/mm2) significantly correlated with PD-L1 positivity (H-score) in tumor cells (Supplementary Materials, Table S1).